AstraZeneca eyes a safer PARP inhibitor, with nearly 50% response in advanced breast cancer patients: #AACR24
SAN DIEGO — AstraZeneca’s experimental PARP1 inhibitor helped shrink tumors in nearly half of people with breast cancers harboring certain DNA repair defects in an early-stage study.
The drug, saruparib, is the most advanced candidate in a new class of compounds that takes aim at the DNA repair enzyme.
While there are several PARP inhibitors already on the market, including AstraZeneca and Merck’s Lynparza and Pfizer’s Talzenna, they target two similar enzymes, PARP1 and PARP2, and cause side effects like nausea, anemia and low white blood cell counts.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
